Open an account

Black Diamond Therapeutics

BDTX · NASDAQ

$2.07+$0.26 (+14.36%)TodayMarket closed ·
Prev close $1.81

About BDTX

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Employees
21
Headquarters
Cambridge, Massachusetts
Listed
Jan 30, 2020
Sector
Health Care
Industry
Biotechnology
Website
blackdiamondtherapeutics.com

BDTX key statistics

Market cap
118.93M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
647.02K
Volume
2.11M
Open price
$1.82
High today
$2.14
Low today
$1.82
52 Week high
$4.94
52 Week low
$1.60

Black Diamond Therapeutics (BDTX) at a glance

As of Oct 20, 2026, Black Diamond Therapeutics (BDTX) shares are priced at $2.07, giving the company a market cap of 118.93M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.82 and $2.14. The current price is 13.7% above the day's low and 3.3% below its high.

Volume so far is 2.11M shares, above the average of 647.02K shares a day.

Over the past year Black Diamond Therapeutics has ranged from $1.60 to $4.94, and now sits 14% of the way up that range.

Black Diamond Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.17 per share against an estimate of -$0.1993.

The average analyst price target is $10.20, 392.8% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 9 analystsAvg $10.20
Low
$8.08
Now
$2.07
High
$14.70

BDTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 649.6% on average.

  1. Q3 FY24: reported -$0.28 per share against an estimate of -$0.3813
  2. Q4 FY24: reported -$0.28 per share against an estimate of -$0.321
  3. Q1 FY25: reported $0.98 per share against an estimate of $0.0217
  4. Q2 FY25: reported -$0.19 per share against an estimate of -$0.2516
  5. Q3 FY25: reported -$0.15 per share against an estimate of -$0.2393
  6. Q4 FY25: reported -$0.27 per share against an estimate of -$0.19
  7. Q1 FY26: reported -$0.16 per share against an estimate of -$0.1884
  8. Q2 FY26: reported -$0.17 per share against an estimate of -$0.1993

BDTX news

  • Press releasePRNewswire

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

  • Avi Kapoor

    US Stocks Mixed; Dollar Tree Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Market-Moving News for March 19th

  • Market-Moving News for September 23rd

Similar companies

Companies in the same industry as Black Diamond Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.